Abstract: Provided is a method of inducing oligodendrocyte precursor cells (OPCs) through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding an Oct4 protein or Oct4 protein-treated human somatic cells. The method of inducing OPCs by treating Oct4-overexpressing human somatic cells with a low molecular weight substance may establish OPCs with high efficiency in a short period of time through direct reprogramming without via neural stem cells, and thus the OPCs are useful as a cell therapeutic agent for an intractable demyelinating disease.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
February 7, 2023
Assignee:
Stemlab Inc.
Inventors:
Seung Kwon You, Won-Jin Yun, Min Ji Park, Ji-Yong Park
Abstract: Provided is a method of inducing oligodendrocyte precursor cells (OPCs) through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding an Oct4 protein or Oct4 protein-treated human somatic cells. The method of inducing OPCs by treating Oct4-overexpressing human somatic cells with a low molecular weight substance may establish OPCs with high efficiency in a short period of time through direct reprogramming without via neural stem cells, and thus the OPCs are useful as a cell therapeutic agent for an intractable demyelinating disease.
Type:
Application
Filed:
August 13, 2020
Publication date:
January 21, 2021
Applicant:
Stemlab Inc.
Inventors:
Seung Kwon YOU, Won-Jin YUN, Min Ji PARK, Ji-Yong PARK
Abstract: Provided is a method of inducing oligodendrocyte precursor cells (OPCs) through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding an Oct4 protein or Oct4 protein-treated human somatic cells. The method of inducing OPCs by treating Oct4-overexpressing human somatic cells with a low molecular weight substance may establish OPCs with high efficiency in a short period of time through direct reprogramming without via neural stem cells, and thus the OPCs are useful as a cell therapeutic agent for an intractable demyelinating disease.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
September 8, 2020
Assignee:
Stemlab Inc.
Inventors:
Seung Kwon You, Won Jin Yun, Min Ji Park, Ji Yong Park
Abstract: The present invention relates to a culture solution of MSCs derived from a fetus in amniotic fluid, and more specifically, to a composition for promoting hair growth or preventing hair loss, which includes a culture solution of MSCs overexpressing a reprogramming factor Nanog and derived from a fetus in amniotic fluid as an active ingredient. In addition, the present invention relates to a method for preparing the composition, which includes culturing Nanog-introduced MSCs derived from a fetus in amniotic fluid in a conditioned medium and collecting the culture solution. The conditioned medium composition according to the present invention exhibits a hair growth promoting effect, and thus is able to be used as cosmetic and pharmaceutical compositions for promoting hair growth.
Type:
Grant
Filed:
September 9, 2016
Date of Patent:
May 5, 2020
Assignee:
Stemlab Inc.
Inventors:
Seung Kwon You, Eun Kyoung Jun, Jung Hyun Park, Won-Jin Yun, Da-Ryeon Son
Abstract: The present invention relates to a method for inducing reprogramming of urine cells into keratinocyte stem cells by introducing reprogramming factors Bmi1 and dNP63a, and a composition for promoting skin regeneration which includes an induced reprogrammed keratinocyte stem cell conditioned medium as an active ingredient.
Type:
Application
Filed:
December 13, 2017
Publication date:
April 16, 2020
Applicant:
Stemlab Inc.
Inventors:
Eun Kyoung JUN, Jie ZHENG, Phil Jn KANG, DaRyeon SON, Ji-Hoon JANG, Won Jun HONG, Jung-Hyun PARK, Gyu Man PARK, In Yong KIM
Abstract: Provided is a method of inducing oligodendrocyte precursor cells (OPCs) through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding an Oct4 protein or Oct4 protein-treated human somatic cells. The method of inducing OPCs by treating Oct4-overexpressing human somatic cells with a low molecular weight substance may establish OPCs with high efficiency in a short period of time through direct reprogramming without via neural stem cells, and thus the OPCs are useful as a cell therapeutic agent for an intractable demyelinating disease.
Type:
Application
Filed:
June 3, 2019
Publication date:
September 19, 2019
Applicant:
Stemlab Inc.
Inventors:
Seung Kwon YOU, Won Jin YUN, Min Ji PARK, Ji Yong PARK